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Abstract
Chronic pain states have resulted in an over-reliance on opioid pain relievers, which can carry 
significant risks when used long-term. As such, alternative pain treatments are increasingly 
desired. Although emerging research suggests that cannabinoids have therapeutic potential 
regarding pain, results from studies across pain populations have been inconsistent. To provide 
meta-analytic clarification regarding cannabis’s impact on subjective pain, we identified studies 
that assessed drug-induced pain modulations under cannabinoid and corresponding placebo 
conditions. A literature search yielded 25 peer-reviewed records that underwent data extraction. 
Baseline and end-point data were used to compute standardized effect size estimates (Cohen’s d) 
across cannabinoid administrations (k = 39) and placebo administrations (k = 26). Standardized 
effects were inverse-variance weighted and pooled across studies for meta-analytic comparison. 
Results revealed that cannabinoid administration produced a medium-to-large effect across 
included studies, Cohen’s d = −0.58, 95% CI (−0.74, −0.43), while placebo administration 
produced a small-to-medium effect, Cohen’s d = −0.39, 95% CI (−0.52, −0.26). Meta-regression 
revealed that cannabinoids, β = −0.43, 95% CI (−0.62, −0.24), p < 0.05, synthetic cannabinoids, β 
= −0.39, 95% CI (−0.65, −0.14), p < 0.05, and sample size, β = 0.01, 95% CI (0.00, 0.01), p < 
0.05, were associated with marked pain reduction. These outcomes suggest that cannabinoid-based 
pharmacotherapies may serve as effective replacement/adjunctive options regarding pain, however, 
additional research is warranted. Additionally, given demonstrated neurocognitive side-effects 
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associated with some constituent cannabinoids (i.e., THC), subsequent work may consider 
developing novel therapeutic agents that capitalize on cannabis’s analgesic properties without 
producing adverse effects.
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Chronic pain is an ever-growing concern in the United States. There is a rising economic 
burden – currently estimated to be between $560 billion and $635 billion annually – that 
stems from pain-related costs to patients, patient-care providers, healthcare systems, and 
poor treatment outcomes among clinical pain populations (e.g., chronic lower back pain, 
neuropathic pain, and fibromyalgia) (Henschke, Kamper, & Maher, 2015). These, and other, 
conditions have resulted in an over-reliance on opioid-based pharmacotherapies. Although 
some patients are appropriate for focused treatments involving opioids (e.g., acute pain), 
patients with more chronic conditions (e.g., cancer) can achieve better outcomes by 
managing pain through more comprehensive approaches (Chou et al., 2009). Thus, it has 
become increasingly important to explore additional therapeutic opportunities. In recent 
decades, cannabinoids – such as molecular compounds found in cannabis, including delta-9-
tetrahydrocannabinol (THC) and cannabidiol (CBD) – have been considered viable 
treatment options regarding pain (Savage et al., 2016). As recently as 2018, 30 states had 
enacted policies that permit cannabis use to treat various medical conditions, with 27 states 
citing pain-related conditions as inclusionary criteria. Despite growing access to medicinal 
cannabis, mixed (and on occasion, null) effects have been reported, underscoring the need to 
expand research efforts regarding cannabinoid-induced pain mitigation.
Recently, several reports have examined cannabinoid administration effects on subjective 
reports of pain (Hill, Palastro, Johnson, & Ditre, 2017). However, these accounts have 
produced variant, and sometimes contradictory, conclusions. In one example, Johnson and 
colleagues (2010) examined the impact of nabiximols (Sativex®), a standardized whole-
plant cannabis extract oromucosal spray, on cancer-related pain. In that double-blind, 
randomized controled trial (RCT), patients with intractable cancer pain entered a two-week 
administration regimen and received THC:CBD extract (2.7 mg THC and 2.5 mg CBD), 
THC extract (2.7 mg THC), or placebo. Patients were free to titrate their dosage as needed. 
Following the drug administration regimen, Johnson et al. observed significant reductions in 
subjective pain ratings among patients receiving THC:CBD extract compared to patients 
receiving placebo. THC alone was less effective. In a similar example, Portenoy and 
colleagues (2012) evaluated nabiximols as an add-on therapy for advanced cancer patients 
with opioid-refractory (unresponsive) pain. Patients were placed into low-, medium-, or 
high-administration conditions and pain was measured following a five-week intervention 
interval. At the end of treatment, Portenoy et al. found that THC:CBD extract was associated 
with greater pain reduction in the low-administration condition (1–4 sprays/day), but not in 
the medium-administration (6–10 sprays/day) or high-administration conditions (11–16 
sprays/day). Taken together, these outcomes suggest that cannabinoids may represent 
potential pharmacological tools for pain reduction. On the other hand, several studies have 
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shown no difference between cannabinoids and corresponding placebo administrations. For 
example, Lichtman and colleagues (2018) leveraged a double-blind RCT to examine pain 
outcomes among cancer patients with uncontrolled pain following a two-week nabiximols 
administration period. Following the intervention, Lichtman et al. compared pain 
modulations from baseline between cannabinoid and placebo conditions, revealing no 
superior effects associated with THC:CBD extract. Moving forward, an important challenge 
facing biomedical research involves coalescing results from studies involving various pain 
populations receiving cannabinoid administrations to determine overall therapeutic potential.
Towards this goal, several systematic reviews have endeavored to summarize cannabis’s 
putative pain-related therapeutic effects (Abrams, 2018; Campbell et al., 2001; Colombo, 
Annovazzi, & Comi, 2006; Deshpande, Mailis-Gagnon, Zoheiry, & Lakha, 2015; Lynch & 
Campbell, 2011; Lynch & Ware, 2015; Sznitman & Zolotov, 2015; Wright, 2007). These 
reviews have provided competing conclusions. In one review, Campbell and colleagues 
(2001) considered outcomes from nine randomized active- and placebo-controlled trials 
involving cannabinoids (five trials involved cancer-related pain, two involved chronic pain, 
and two acute post-operative pain), with a focus on pain intenseness scores, pain relief 
scores, and adverse effects. Those authors concluded that the cannabinoids considered were 
no more effective than active control conditions, including the opioid analgesic codeine, 
stressing that cannabinoid administration to treat post-operative pain would be 
“undesirable,” given unwanted central nervous system depressant effects. However, opioids 
have also been linked with depressant/sedative effects (Chou et al., 2009). Moreover, other – 
perhaps more severe – opioid-related adverse effects include respiratory depression, 
especially when paired with other substances, such as benzodiazepines and alcohol (Chou et 
al., 2009). Given the abuse potential associated with opioids, these (and other) side-effects 
underscore the need to consider replacement and/or adjunctive pain management 
approaches. Additionally, Campbell et al. noted that, among RCTs considered in the 
systematic review, none had examined active cannabis. That is, the trials examined pain 
reduction associated with THC, nitrogen-containing benzopyran derivative, 
benzopyranoperidine, or levonantradol. Importantly, cannabinoid-induced analgesia may 
stem from compound or synergistic effects associated with several cannabinoids. For 
example, preclinical evidence suggests that high-dose CBD modulates antinociceptive 
effects associated with low-dose THC, indicating that both cannabinoids may be involved in 
pain reduction (Varvel et al., 2006). Furthermore, work from Comelli and colleagues 
(Comelli, Giagnoni, Bettoni, Colleoni, & Costa, 2008) demonstrates that whole-plant 
cannabis extract provides improved nociceptive efficacy compared to corresponding doses of 
constituent cannabinoids. As such, as the corpus of cannabis-related pain investigations 
continues growing, it is possible that more comprehensive assessments could reach 
alternative conclusions regarding cannabinoid analgesia. In a more recent review, The 
National Academies of Sciences, Engineering and Medicine considered more than 10,000 
peer-reviewed abstracts to characterize cannabis’s potential therapeutic utility across several 
domains, including pain. That committee concluded that “there was conclusive or substantial 
evidence that Cannabis or cannabinoids are effective for the treatment of pain in adults,” 
(Abrams, 2018). However, narrative and systematic reviews often omit representative 
estimates of effect magnitude and therefore cannot provide quantitative conclusions about 
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outcomes of interest. As such, objective techniques that determine statistical convergence 
across published studies involving cannabinoid-induced pain reduction are needed to more 
accurately characterize potential therapeutic effects.
Meta-analyses present powerful opportunities to coalesce conventional effect size estimates 
(e.g., Cohen’s d) across published studies, providing clarification regarding results and 
permitting assessments not possible within the original, single report. Within this 
framework, several study-level effect size estimates derived under comparable experimental 
conditions are averaged, producing one pooled (representative) effect size estimate (Hedges 
& Olkin, 1985). Regarding pharmacologic manipulations, pooled effect sizes are used to 
characterize cross-study drug administration effects on specific end-points (Wilkinson et al., 
2018), or to make comparisons between two (or more) drug administration conditions 
(Bushe et al., 2016). Towards this goal, several meta-analyses have provided some insight 
into cannabinoid-related pain reduction (Andreae et al., 2015; Aviram & Samuelly-Leichtag, 
2017; De Vita, Moskal, Maisto, & Ansell, 2018; Goldenberg, Reid, IsHak, & Danovitch, 
2017; Iskedjian, Bereza, Gordon, Piwko, & Einarson, 2007; Martin-Sanchez, Furukawa, 
Taylor, & Martin, 2009; Phillips, Cherry, Cox, Marshall, & Rice, 2010; Whiting et al., 
2015). For example, Iskedjian and colleagues (2007) synthesized results from six studies 
examining cannabinoid administration within the limited context of multiple sclerosis (MS). 
When considering baseline versus end-point pain ratings among 298 patients, Iskedjian et al. 
observed that cannabinoids were associated with greater pain reduction relative to placebo. 
However, whether these effects extend beyond MS-related pain (e.g., neuropathic pain) 
remained unclear. In a more comprehensive meta-analysis, Aviram and Samuelly-Leichtag 
(2017) examined pain reduction associated with cannabinoid-based medicines across 24 
RCTs. Those researchers considered several pain populations, including neuropathic pain, 
cancer-related pain, non-cancer pain, and post-operative pain, as well as active-control and 
placebo-control designs. Overall, Aviram and Samuelly-Leichtag reported “limited” support 
for cannabinoid-based medicines across considered RCTs. However, a more focused 
assessment that excluded active-control designs – which were believed to have increased 
analgesic efficacy compared to placebo – demonstrated improved analgesic outcomes 
associated with cannabinoid-based medicines. Surprisingly, the extent to which specific 
study-level characteristics, such as sample size, age, and sex composition (sex ratio), may 
modulate observed pain outcomes remains to be meta-analytically explored. Indeed, these 
active research areas have received considerable attention in recent years (Lauer, 2016). 
Here, we address this open-ended question using meta-regression to examine cannabinoid- 
and placebo-related pain reduction with respect to several study-level characteristics (Baker 
et al., 2009).
To determine cross-study cannabinoid-related standardized effect sizes regarding self-
reported pain reduction, and to examine potential associations with important study-level 
characteristics, we leveraged a combined meta-analysis and meta-regression approach. In a 
primary assessment, we used meta-analysis techniques to coalesce drug-induced pain 
reduction standardized effect sizes associated with cannabinoid and placebo administrations 
to produce pooled effects and enable statistical comparison. In a second assessment (Glass, 
Smith, & McGaw, 1981), we used meta-regression to examine relationships between various 
continuous and categorical explanatory variables and drug-induced pain reduction effect 
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sizes. Specifically, we used multiple linear regression to examine relationships between 
several study-level characteristics (sample size, age, sex composition, experimental design, 
and pain population) and drug administration conditions. Overall, we posited that 
cannabinoid administration would be associated with pain reduction across included studies, 
and that placebo administration would be less effective. Furthermore, we expected that 
study-level characteristics would be associated with pain reduction standardized effect sizes. 
Providing clarification about potential pain-mitigating effects associated with cannabinoids 
should enable enhanced scientific understanding about possible therapeutic applications.
Methods
Search
We conducted a literature search to identify pharmacological manipulation studies that 
assessed cannabinoid-induced alterations in subjective pain ratings. Primary searches were 
carried out using PudMed (www.ncbi.nlm.nih.gov/pumed/) and Web of Science (http://
webofknowledge.com) with the search terms: cannabis OR cannabinoids OR delta-9-
tetrahydrocannabinol OR THC OR cannabidiol OR CBD OR marijuana OR nabilone OR 
dronabinol OR nabiximols AND pain OR noxious OR analgesia OR visual analog scale OR 
VAS OR numeric rating scale OR NRS. We further reviewed the reference sections of each 
record identified during the exhaustive search, in particular, systematic and narrative review 
papers (Campbell et al., 2001; Colombo et al., 2006; Deshpande et al., 2015; Lynch & 
Campbell, 2011; Lynch & Ware, 2015; Sznitman & Zolotov, 2015; Wright, 2007) and 
existing meta-analyses (Andreae et al., 2015; Aviram & Samuelly-Leichtag, 2017; De Vita 
et al., 2018; Goldenberg et al., 2017; Iskedjian et al., 2007; Martin-Sanchez et al., 2009; 
Phillips et al., 2010)
Screen
During screening, record abstracts were inspected to determine appropriateness. Specifically, 
records that did not represent peer-reviewed original research studies were removed from the 
meta-analysis review pipeline (e.g., letters to editors, reviews, conference proceedings). 
Records involving non-human models were also not considered. This meta-analysis was 
restricted to RCTs that: (A) assessed drug-induced pain reductions following cannabinoid 
administration across studies, including whole-plant cannabis, whole-plant cannabis 
extracts, and synthetic cannabinoids (i.e., Dronabinol, Nabilone, CT3), and corresponding 
active or placebo administrations, (B) described pain reductions as differences between 
baseline (pre-administration) and end-point (post-administration) measurements, and (C) 
used a parallel-groups (i.e., independent samples) or crossover (i.e., repeated measures) 
design to examine pain reductions. Importantly, although active control studies were 
considered in the current meta-analysis (Frank, Serpell, Hughes, Matthews, & Kapur, 2008; 
Pini et al., 2012), drug-induced pain reductions associated with active control administration 
(e.g., ibuprofen) were not included in placebo sub-group analyses. The current meta-analysis 
reflects papers published through August 2018.
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Data Extraction and Primary Meta-Analysis
Remaining records were obtained as complete published articles and assessed by two 
reviewers (J.A.Y and Z.E.M). Reviewers cross-checked extracted data points and resolved 
disagreement before commencing meta-analyses. Extracted data points included: author, 
publication year, sample size(s), pharmacological manipulation(s) (whole-plant cannabis, 
whole-plant cannabis extract, synthetic cannabinoid, and placebo), pain population (pain 
linked with various medical conditions), baseline mean pain score, end-point mean pain 
score, and associated variance estimates. Studies that involved more than two (ki) 
administration conditions (e.g., THC:CBD extract, THC extract, and placebo) contributed ki 
(k = 3) mean gain standardized effect sizes to quantitative assessment, where k describes 
total standardized effect sizes considered in the current meta-analysis. Because we sought to 
pool cannabinoid-related standardized effect sizes across included studies, and because we 
sought to pool placebo-related standardized effect sizes across included studies, baseline and 
end-point pain severity scores were extracted from cannabinoid and placebo conditions 
separately. Studies that omitted baseline and/or end-point pain severity scores were 
excluded. When required, pain severity scores were computed using available summary data 
(e.g., mean pain percent reduction (Abrams et al., 2007; Johnson et al., 2010; Langford et 
al., 2013; Narang et al., 2008; Skrabek, Galimova, Ethans, & Perry, 2008). Data points 
collected from one record required reverse scoring (Wade, Robson, House, Makela, & Aram, 
2003). Although baseline and end-point pain severity scores were necessary for inclusion, 
several records omitted associated variance estimates (Abrams et al., 2007; Blake, Robson, 
Ho, Jubb, & McCabe, 2006; Buggy et al., 2003; Chou et al., 2009; Corey-Bloom et al., 
2012; Johnson et al., 2010; Karst et al., 2003; Langford et al., 2013; Narang et al., 2008; 
Nurmikko et al., 2007; Portenoy et al., 2012; Rog, Nurmikko, Friede, & Young, 2005; 
Skrabek et al., 2008; Svendsen, Jensen, & Bach, 2004; Wilsey et al., 2008). In such cases, 
we employed several strategies to secure missing variance data. First, we contacted the lead 
and/or corresponding authors with data requests. Second, to supplement remaining records, 
we leveraged the freely available service WebPlotDigitizer (https://automeris.io/
WebPlotDigitizer) to compute variance estimates using manuscript figures – an accepted 
technique to extract numeral data from data visualizations (Rohatgi, 2018). Third, when data 
requests and data extraction from visualizations were not possible, missing variance 
estimates were reconciled via mean imputation using assembled variance estimates (Cooper, 
Hedges, & Valentine, 2009). Notably, imputed variance estimates represented approximately 
35% (46/130) of total variance data. Outcome measures included quantitative pain-rating 
scales, such as numeric rating scales (NRS) (Hartrick, Kovan, & Shapiro, 2003) and visual 
analog scales (VAS) (Ferraz et al., 1990). Quantitative pain-rating scales involve asking 
participants to describe pain severity, routinely anchored by zero, indicating “no pain,” and 
10, indicating “worst pain.” Results from studies using 100-point ranges were scaled to 
enable pooling and comparison.
Following data extraction, baseline pain severity scores, end-point pain severity scores, and 
associated variance estimates, were used to compute study-level standardized mean gain 
effect size (i.e., Cohen’s d) (Becker, 1988). Standardized effect sizes were used to calculate 
associated standard errors (Lipsey & Wilson, 2001) and confidence intervals (Nakagawa & 
Cuthill, 2007). To facilitate meta-analytic comparison, study-level standardized effect sizes 
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were then inverse-variance weighted and pooled to produce an average cannabinoid-induced 
effect and an average placebo-induced effect (Hedges & Olkin, 1985). Monte Carlo 
simulations suggest that inverse-variance weighting produces optimal pooled effect sizes in 
meta-analysis assessments (Sánchez-Meca & Marin-Martinez, 1998). Forest plots were 
created to visualize standardized effect sizes. We assessed the degree to which variation 
among cannabinoid and placebo administrations was attributed to chance via the I2 statistic 
and associated confidence intervals (Higgins & Thompson, 2002; Higgins, Thompson, 
Deeks, & Altman, 2003). Pooled effects were compared with an independent-samples mean 
difference test (Hedges & Olkin, 1985; Hedges & Pigott, 2001).
Multiple Linear Regression (Meta-Regression)
Meta-regression examines the relationships between continuous and/or categorical 
explanatory variables (e.g., sample size, sample age, sample sex composition) and a 
continuous outcome variable (e.g., study-level standardized effect sizes) (Green & Higgins, 
2005). Specifically, we used an exploratory fixed-effects multiple linear regression (meta-
regression) approach (Greenland, 1987; Luebke & Brunkwall, 2015), to explore 
relationships between pain reduction effects and: drug administration condition [placebo, 
cannabinoid (whole-plant, whole-plant extract), synthetic cannabinoid (Dronabinol, 
Nabilone, CT3)], sample size (reported sample size), sample age (mean sample age), sample 
sex composition (sample sex ratio), experimental design (parallel versus crossover), and pain 
population (abdominal pain, arthritis, cancer, chronic pain, diabetes, fibromyalgia, headache, 
human immunodeficiency virus (HIV), multiple sclerosis, neuropathic pain, post-operative 
pain, and “various,” or mixed pain populations within one effect). Data were examined using 
statistical assumptions associated with regression, including normality, residual normality, 
and equal variances. Outliers among standardized effect sizes [i.e., median effect +/− 
interquartile range (IQR) × 1.5] were adjusted using upper/lower quartile replacement 
(Tukey, 1977). Categorical variables (e.g., placebo, cannabinoid, synthetic cannabinoid) 
were dummy coded to facilitate meta-regression assessment (Wolf & Cartwright, 1974).
Ethics and Open Science Practices
As is common with meta-analytic assessments, the current report did not involve human 
subjects and therefore did not require institutional review board approval (Sullivan, 2011). In 
line with current recommendations and open science best practices (Open Science, 2015), 
we have made meta-data and corresponding code associated with this work freely available 
on GitHub (https://doi.org/10.5281/zenodo.1463262).
Results
Primary Meta-Analysis
Literature search and review results are depicted in Table 1 and Figure 1. The search 
produced 954 records which underwent screening. Using exclusion criteria described above, 
899 records were removed during abstract review, and another 30 were removed during full-
text review. The current meta-analysis included data from 25 records that met inclusion 
criteria, providing data from k = 65 individual pharmacologic manipulations (39 
cannabinoid manipulations versus 26 placebo manipulations), involving 2,248 participants. 
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On average, studies reported that participants’ mean age ranged from 43.50 to 62.80 years 
(mean = 52.09). Included studies assessed drug-induced pain reductions associated with 
several cannabinoid administration conditions, including whole-plant cannabis (n = 5), 
whole-plant cannabis extract (n = 11), and synthetic cannabinoids (n = 9). Pain-related 
clinical samples (pain populations) considered were neuropathic pain (n = 7), cancer (n = 4) 
diabetes (n = 3), MS (n = 3), abdominal pain (n = 1), arthritis (n = 1), chronic pain (n = 1), 
fibromyalgia (n = 1), headache (n = 1), HIV (n = 1), post-operative pain (n = 1), and 
“various” (n = 1). Standardized effect sizes are organized according to pain population in 
Supplemental Figure 1. On average, studies reported that 51.57% of participants were 
women. Fifteen studies provided data from parallel-group designs and 10 provided data 
from crossover designs.
Inverse-variance weighting and pooling across cannabinoid standardized effect sizes 
revealed that cannabinoid administration was associated with a ‘medium-to-large’ effect, 
Cohen’s d = −0.58, 95% CI (−0.74, −0.43) (Figure 2). An assessment of variation revealed 
considerable heterogeneity among cannabinoid effect sizes, I2 = 91.47%, 95% CI (87.93%, 
92.37%). On the other hand, inverse-variance weighting and pooling across placebo 
standardized effect sizes revealed that placebo administration was associated with a ‘small-
to-medium’ effect, Cohen’s d = −0.39, 95% CI (−0.52, −0.26) (Figure 3). An assessment of 
variation revealed considerable heterogeneity among placebo effect sizes, I2 = 92.66%, 95% 
CI (89.18%, 93.70%). Overall, cannabinoid administration was associated with greater pain 
reduction compared to placebo administration, t (64) = −4.06, p < 0.05. Visual inspection 
revealed some overlap between drug administration condition confidence intervals.
Exploratory Multiple Linear Regression (Meta-Regression)
Overall, the meta-regression model explained a moderate proportion of variance among 
individual studies, R2 = 0.37 (adjusted R2 = 0.30), F (6,48) = 4.62, p < 0.05. Reported p-
values are associated with corresponding coefficient hypotheses tests. Meta-regression 
results revealed that, when controlling for other explanatory variables, drug administration 
conditions were linked with pain reduction among included studies, such that cannabinoids 
(whole-plant cannabis and whole-cannabis extracts) β = −0.43, 95% CI (−0.62, −0.24), p < 
0.05 (Figure 4), and synthetic cannabinoids (Dronabinol, Nabilone, and CT3) β = −0.39, 
95% CI (−0.65, −0.14), p < 0.05 (Figure 4), performed better than placebo. Furthermore, 
meta-regression results showed that, when controlling for other explanatory variables, 
sample size was linked with pain reduction, β = 0.01, 95% CI (0.00, 0.01), p < 0.05, such 
that studies involving smaller samples tended to report greater pain reduction effects (Figure 
4). There were no observed interactions between drug administration conditions and sample 
size. Finally, meta-regression results showed that, when controlling for other explanatory 
variables, sample sex composition was linked with a modest, however non-significant, 
effect, β = −0.64, 95% CI (−1.37, 0.09), p = 0.09, such that studies including more female 
participants tended to report greater pain reductions (Figure 5).
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Discussion
In this meta-analytic study, we coalesced results from peer-reviewed primary research 
articles that characterized cannabinoid- and placebo-induced reductions of subjective pain 
ratings across medical conditions. Our findings extend current understanding about 
cannabinoids and pain, taking a meta-regression approach to examine relationships between 
various study-level characteristics and drug-induced pain reductions. When considering 
reductions in self-reported pain, we observed that cannabinoid administration was associated 
with a ‘medium-to-large’ (Cohen, 1988) pooled effect size across included studies. 
Importantly, cannabinoid administration was associated with statistically significant greater 
pain reduction than placebo administration, which yielded a ‘small-to-medium’ (Cohen, 
1988) pooled effect size. Indeed, placebo administration has been shown to enhance 
expectations about pain reduction (Bushe et al., 2016), potentially assuaging negative 
emotional/motivational aspects about pain experiences. Finally, results from our meta-
regression analysis suggested that, when controlling for other explanatory variables, drug 
administration conditions and sample size predicted observed pain reduction. Taken 
together, these meta-analytic outcomes provide some evidence that cannabinoids, relative to 
placebo, might mitigate subjective pain reporting among those experiencing chronic pain 
tied to various medical conditions. However, more research is needed to understand nuances 
in cannabinoid-induced pain reduction, including outcome differences between single-dose 
versus long-term cannabinoid treatments, complex interactions with concurrent analgesic 
pharmacotherapies, and changes in cannabis conditional dependence rates as a function of 
increased access.
Neuropsychological Impact of Cannabinoid-Based Administrations
When considering cannabis’s effect on pain, our primary meta-analysis outcomes suggest 
that cannabinoids may represent a viable option regarding pain management and treatment- 
outperforming corresponding placebo conditions across included studies. That cannabinoids 
were associated with pain reduction is not surprising, given that the most common medicinal 
cannabis applications throughout documented human history involve administration for pain 
(Parker, 2017). Indeed, early evidence suggests that medicinal cannabis may have been used 
to relieve pain around 400 CE (Zlas et al., 1993). However, it was just in the 1990s that 
several reports described an endogenous cannabinoid framework embedded within the 
central nervous system (Devane et al., 1992) and peripheral nervous system (Munro, 
Thomas, & Abu-Shaar, 1993), which interacts with exogenous cannabinoids to modulate 
pain.
Processing pain signals starts with nociceptive sensation signal transduction throughout the 
peripheral nervous system and terminates with subjective pain perception within the central 
nervous system (for an exteded review, see Millan, 1999). First, peripheral sensory neurons 
detect noxious stimulation, which is then communicated to neuronal bodies around the 
spinal column. Next, sensory neurons synapse onto central dorsal horn neurons within the 
spinal cord, where pain signals are integrated across pathways. Finally, central dorsal horn 
neurons forward pain signals via ascending pathways to the brainstem, thalamus, and 
cortical brain regions, which process higher-order pain behavior. Notably, cannabinoid 
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receptors are densely concentrated in the frontal and limbic cortices- brain regions also 
associated with processing pain, including the anterior cingulate cortex (ACC) (Glass, Faull, 
& Dragunow, 1997). As such, cannabinoid receptor agonists may work to mitigate 
subjective pain experiences via interactions with brain regions responsible for processing 
more complex mental operations, such as pain-related affective and motivational 
dimensions. Consistent with such an interpretation, recent reports have examined the 
relationship between cannabis and pain-related brain function. For example, Lee and 
colleagues (2013) used functional magnetic resonance imaging (fMRI) to investigate 
cannabis’s impact on blood-oxygen-level dependent (BOLD) signal fluctuations in response 
to experimental chemical pain (i.e., capsaicin) among normal participants. Those researchers 
observed that, when compared to placebo, cannabinoid administration (i.e., 15 mg THC) 
reduced pain unpleasantness, but not pain intenseness. That is, cannabinoid administration 
may modulate pain perception (unpleasantness) without affecting pain sensation 
(intenseness), a position supported by a recent meta-analysis of cannabinoid-induced 
modulations in experimental pain (De Vita et al., 2018). Moreover, cannabinoid-induced 
reductions in pain unpleasantness correlated with less ACC activation. Indeed, ACC 
functioning has been implicated in various affective-motivational components in higher-
order pain processing, such as conditioned place avoidance (Johansen, Fields, & Manning, 
2001; LaGraize, Labuda, Rutledge, Jackson, & Fuchs, 2004), perceived threat from noxious 
stimulation (Foltz & White Jr, 1962), and monitoring survival-relevant goals (Lieberman & 
Eisenberger, 2015). Although acute cannabinoid receptor agonism dampens ACC 
responding to pain, effectively reducing pain-related negative affect, whether these effects 
endure beyond acute administration remains unclear. In a recent neuroimaging meta-
analysis, Yanes and colleagues (2018) examined neurofunctional alterations associated with 
chronic cannabis use. When considering cannabis’s impact across various mental tasks, 
those researchers observed that chronic cannabis was linked with, among other changes, 
decreased ACC activation. Furthermore, ancillary assessments revealed that activity within 
the ACC has been consistently linked with pain-related taxonomic descriptors (i.e., Pain, 
Pain Monitor/Discrimination) across the functional neuroimaging literature. To summarize, 
the neurobiological outcomes discussed here may represent potential higher-order, brain-
level mechanisms that support demonstrated cannabis-induced pain reduction.
Outcomes from Meta-Regression
Meta-regression results showed that sample size was associated with pain reduction 
standardized effect sizes across studies, such that studies involving smaller samples reported 
greater pain reduction. Moreover, there was no interaction between reported sample size and 
drug administration conditions (i.e., cannabinoid, synthetic cannabinoid, and placebo), 
suggesting that this was the case across pharmacologic manipulations considered. Sample 
size represents an important determinant regarding how generalizable research results are to 
target populations (Wiedermann & Wiedermann, 2015). Often, studies with smaller samples 
have reported better therapeutic outcomes (Sterne & Egger, 2001). This phenomenon has 
been linked to outcome reporting biases (Chan & Altman, 2005), such as data omission 
when results lack statistical significance, poorer methodological parameters (Kjaergard, 
Villumsen, & Gluud, 2001), and increased between-study heterogeneity among studies with 
small samples (IntHout, Ioannidis, Borm, & Goeman, 2015). Moving forward, it is 
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important that researchers, healthcare providers, and law makers consider outcomes from 
studies on cannabinoid-induced pain reductions within the context of the sample sizes that 
derived them.
When considering sex-dependent effects in cannabinoid-induced pain reduction, meta-
regression results suggested that among included studies, those studies that recruited more 
female participants reported greater, although non-significant, standardized effect sizes 
across drug administration conditions. It is worth noting that meta-regression outcomes 
derived using summary statistics (e.g., sample sex composition) may exhibit ecological 
confounding (Morgenstern, 1982) compared to using patient-level data (Thompson & 
Higgins, 2002). As such, the relationship between biological sex and cannabinoid analgesia 
should become clearer as new studies emerge that provide within-sample comparisons. 
Accumulating preclinical evidence suggests that females may be more sensitive to 
cannabis’s pain-reducing effects. Indeed, greater pain reduction among females following 
cannabinoid-receptor agonism has been shown in acute pain and non-acute pain animal 
models (Craft, Marusich, & Wiley, 2013; Craft, Wakley, Tsutsui, & Laggart, 2012; Tseng & 
Craft, 2001). However, whether these sex-dependent effects extend to humans remains 
unclear. One recent report from Cooper and Haney (2016) examined pain reduction among 
male and female cannabis users following active cannabis consumption (3.65–5.60% THC) 
and placebo consumption (0.00% THC). Among male cannabis users, those researchers 
found that cannabis consumption increased pain-onset latency compared to placebo- 
presumably by reducing pain sensitivity. Among female cannabis users, however, no 
differences were observed between active cannabis and placebo conditions. These discordant 
outcomes may highlight important nuances about cannabinoid-related reductions in reported 
pain. Specifically, findings from the current meta-analysis represent data from participants 
with various clinical conditions. Growing evidence suggests that women experience greater 
clinical pain (Rosseland & Stubhaug, 2004; Unruh, 1996), often endorsing increased pain-
related distress (Paller, Campbell, Edwards, & Dobs, 2009). It is then possible that reported 
sex-differences in cannabinoid-induced pain reduction stem from differences in pain 
reporting- not pain sensation and/or perception. With this in mind, one important question 
facing subsequent research involves our current understanding of sex-dependent effects in 
cannabinoid-induced pain reduction. Moreover, subsequent research may consider sex 
differences across complimentary pain outcomes, such as pain tolerance, pain ratings, and 
pain questionnaires/scales.
Limitations
Findings presented here should be considered in the context of several methodological 
limitations. First, as is common with meta-analyses, our outcomes and associated 
interpretations are constrained by the state of the current literature. Accordingly, results 
obtained here should be considered preliminary given the modest sample size (i.e., 25 
papers). Moreover, recommendations regarding sub-group analyses and meta-analytic 
modeling prevented more refined assessments, such as estimating standardized effect sizes 
as a function of cannabinoid sub-classifications (e.g., whole-plant cannabis, whole-plant 
cannabis extract, synthetic cannabinoid, THC, CBD, THC/CBD), dose (e.g., 2.5mg THC, 
5mg THC), administration route (e.g., smoke, oromucosal spray, capsule), and pain 
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population (e.g., central/peripheral neuropathic pain, cancer pain, multiple sclerosis pain) 
(Green & Higgins, 2005). The inclusion of studies that involved several drug conditions and 
clinical samples into the same meta-analysis presumably contributed to observed between-
study heterogeneity. More granular meta-analytic approaches should become possible as 
additional relevant studies are made available. Second, even though included studies 
involved comparable end-point measures (i.e., numeric rating scale, visual analog scale), 
these studies may contain confounds and/or biases that have not been addressed, such as 
temporal variation in societal attitudes towards cannabis, regional policies that promote 
medicinal cannabis, and inter-individual differences regarding cannabis’s expected 
effectiveness. With this in mind, we used fixed-effects multiple linear regression (meta-
regression) to control confounding effects where possible (e.g., experimental design) 
(Stanley & Jarrell, 1989). Also, moving forward, researchers may consider systematically 
collecting/reporting concomitant end-point measures [e.g., McGill Pain Questionnaire 
(Melzack, 1975)], to provide more complete characterizations of cannabis-related analgesic 
effects. Third, despite rigorous review methods, several records were excluded from the 
current meta-analysis due to missing data. According to the Open Science Collaboration 
(2015), problematic practices within psychological science include selective reporting, 
omitting analyses, and insufficient specification regarding experimental parameters. 
Moreover, the current meta-analysis cannot consider studies that were conducted but never 
reported (i.e., “the file drawer problem”) (Rosenthal, 1979). Thus, improved reporting 
practices should enable enhanced meta-analysis assessments in general, and regarding 
cannabinoids in particular. Finally, despite showing that cannabinoid administration was 
associated with pain reduction, many studies included in this meta-analysis did not give full 
consideration to neurocognitive side-effects linked with cannabis (for an extended review, 
see Crane, Schuster, Fusar-Poli, & Gonzalez, 2013). Future investigations should 
systematically examine cannabis’s therapeutic properties in the context of co-occurring 
undesired neurocognitive effects.
Conclusions
Our meta-analysis outcomes show that cannabinoid administration was associated with 
reductions in subjective pain across included studies, making them viable candidates for 
pain management and treatment. Moreover, meta-regression results suggested that drug 
administration condition and sample size predicted pain reduction effects. Finally, we 
observed that sample sex composition was associated (although, not statistically significant) 
with observed pain reduction, suggesting that this may be an important biological variable 
when considering cannabis-induced pain reduction. As social, societal, and political attitudes 
towards cannabis evolve, it is becoming increasingly important to provide enhanced 
scientific understanding regarding risks and potential therapeutic applications. Such 
understanding should lead to more informed decision-making regarding cannabis among 
patients, care providers, and law makers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Public Significance Statement
Chronic pain states are an ever-growing concern in the United States, costing an 
estimated $600 billion annually in lost labor and healthcare expenses. These, and other, 
conditions have resulted in an over-reliance on opioid-based pharmacotherapies. Results 
from the current meta-analysis provide some support that cannabinoids might mitigate 
subjective pain among patients with pain-related clinical conditions.
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Figure 1. Literature Search and Review Pipeline.
Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) pipeline 
diagram showing search and review results. A preliminary search produced 949 records, 
with an additional 5 assembled from additional resources (e.g., narrative reviews), totaling 
954 records overall. During abstract review, 899 records were removed from the meta-
analysis pipeline. During complete manuscript review, an additional 30 records were 
discarded based on study exclusion criteria. Finally, the 25 remaining records underwent 
data extraction and subsequent meta-analytic assessment.
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Figure 2. Pooled Cannabinoid Administration Effect.
Study-level standardized effect size estimates (Cohen’s d) were computed for each 
cannabinoid administration across included studies. Circle sizes are proportional to small, 
medium, and large effect size estimate interpretations (Cohen, 1988). Study-level estimates 
were inverse-variance weighted and pooled to determine a representative estimate. When 
considering overall pain reduction effects, cannabinoid administration was associated with a 
medium-to-large effect across studies, Cohen’s d = −0.58, 95% CI (−0.74, −0.43).
N, sample size; ES, standardized effect size estimate; CI, confidence interval.
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Figure 3. Pooled Placebo Administration Effect.
Study-level standardized effect size estimates (Cohen’s d) were computed for each placebo 
administration across included studies. Circle sizes are proportional to small, medium, and 
large effect size estimate interpretations (Cohen, 1988). Study-level estimates were inverse-
variance weighted and pooled to determine a representative estimate. When considering 
overall pain reduction effects, placebo administration was associated with a small-to-
medium effect across studies, Cohen’s d = −0.39, 95% CI (−0.52, −0.26).
N, sample size; ES, standardized effect size estimate; CI, confidence interval.
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Figure 4. Bivariate Relationship Between Effect Size Estimates and Significant Predictors.
Meta-regression results revealed that, when controlling for other explanatory variables, drug 
administration conditions were linked with pain reduction among included studies, such that 
cannabinoids (whole-plant cannabis and whole-cannabis extracts) β = −0.43, 95% CI 
(−0.62, −0.24), p < 0.05, and synthetic cannabinoids (Dronabinol, Nabilone, and CT3) β = 
−0.39, 95% CI (−0.62, −0.24), p < 0.05, performed better than placebo. Furthermore, meta-
regression results showed that, when controlling for other explanatory variables, sample size 
was linked with pain reduction, β = 0.01, 95% CI (0.00, 0.01), p < 0.05, such that studies 
involving smaller samples tended to report greater pain reduction.
Cannabinoids = shaded (green) circles; placebo = unshaded circles.
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Figure 5. Bivariate Relationship Between Effect Size Estimates and Sample Sex Composition 
(Sex Ratio).
Meta-regression results showed that, when controlling for other explanatory variables, 
sample sex composition was linked with a modest, albeit non-significant, effect, β = −0.64, 
95% CI (−1.37, 0.09), p = 0.09, such that studies including more female participants tended 
to report greater pain reductions.
Cannabinoids = shaded (green) circles; placebo = unshaded circles.
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Table 1.
Studies Meeting Inclusion Criteria.
Numbering corresponds to studies meeting inclusion criteria. Extracted variables were administration 
condition (administration), including cannabis whole plant, cannabis extract, synthetic cannabinoid, and 
placebo, administration dose (dose), administration route (route), population with pain-related clinical 
condition (pain population), subjective pain outcome measure (pain measure), and associated scale (scale). 
THC, delta-9-tetrahydrocannabinol; CBD, cannabidiol. CT3, dimethylheptyl-delta-8-tetrahydrocannabinol-11-
oic acid; HIV, human immunodeficiency virus;
No. Author Year
Details Regarding Sampled Studies
Administration Dose Route Pain Population Pain Measure Scale
1 Abrams et al. 2007 Whole Plant 3.56 % THC Smoke HIV Visual Analog Scale 0 – 100
2 Blake et al. 2006 Extract (Sativex) 2.7 mg 
THC / 2.5 
mg CBD
Oromucosal Spray Arthritis Numeric Rating Scale 0 – 10
3 Buggy et al. 2003 Extract 5.0 mg THC Capsule Post-Operation Visual Analog Scale 0 – 10
4 Corey-Bloom et al. 2012 Whole Plant 4.0% THC Cigarette Multiple Sclerosis Visual Analog Scale 0 – 100
5 De Vries et al. 2017 Synthetic (Dronabinol; 8 mg Tablet Abdominal Pain Visual Analog Scale 0 – 10
De Vries et al. 2017 Synthetic (Dronabinol) 8 mg Tablet Abdominal Pain Visual Analog Scale 0 – 10
6 Fallon et al. 2017 Extract (Sativex) 2.7 mg 
THC / 2.5 
mg CBD
Capsule Cancer Numeric Rating Scale 0 – 10
7 Frank et al. 2008 Synthetic (Nabilone) 0.25 mg Capsule Neuropathic Pain Visual Analog Scale 0 – 100
8 Johnson et al. 2010 Extract (Sativex) 2.7 mg 
THC / 2.5 
mg CBD
Capsule Cancer Numeric Rating Scale 0 – 10
Extract 2.7 mg THC Capsule Cancer Numeric Rating Scale 0 – 10
9 Karst et al. 2003 Synthetic (CT-3) 10.0 mg Capsule Neuropathic Pain Visual Analog Scale 0 – 100
10 Langford et al. 2012 Extract (Sativex) 2.7 mg 
THC / 2.5 
mg CBD
Oromucosal Spray Neuropathic Pain Numeric Rating Scale 0 – 10
11 Lichtman et al. 2017 Extract (Sativex) 2.7 mg 
THC / 2.5 
mg CBD
Cancer Numeric Rating Scale 0 – 10
12 Narang et al. 2008 Synthetic (Dronabinol) 20.0 mg Capsule Chronic Pain Numeric Rating Scale 0 – 10
2008 Synthetic (Dronabinol) 10.0 mg Capsule Chronic Pain Numeric Rating Scale 0 – 10
13 Nurmikko et al. 2007 Extract (Sativex) 2.7 mg 
THC / 2.5 
mg CBD
Oromucosal Spray Neuropathic Pain Numeric Rating Scale 0 – 10
14 Pini et al. 2012 Synthetic (Nabilone) 0.5 mg Capsule Headache Visual Analog Scale 0 – 10
15 Portenoy et al. 2012 Extract (Sativex) 2.7 mg 
THC / 2.5 
mg CBD
Oromucosal Spray Cancer Visual Analog Scale 0 – 10
Extract (Sativex) 2.7 mg 
THC / 2.5 
mg CBD
Oromucosal Spray Cancer Visual Analog Scale 0 – 10
Extract (Sativex) 2.7 mg 
THC / 2.5 
mg CBD
Oromucosal Spray Cancer Visual Analog Scale 0 – 10
16 Rog et al. 2007 Extract (Sativex) 2.7 mg 
THC / 2.5 
mg CBD
Oromucosal Spray Neuropathic Pain Numeric Rating Scale 0 – 10
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No. Author Year
Details Regarding Sampled Studies
Administration Dose Route Pain Population Pain Measure Scale
17 Schimrigk et al. 2017 Synthtic (Nabilone) 7.5 mg – 
15.0 mg
Capsule Multiple Sclerosis Numeric Rating Scale 0 – 10
18 Selvarajah et al. 2010 Extract (Sativex) 2.7 mg 
THC / 2.5 
mg CBD
Oromucosal Spray Diabetes Visual Analog Scale 0 – 100
29 Skrabek et al. 2007 Synthetic (Nabilone) 0.5 mg Capsule Fibromyalgia Visual Analog Scale 0 – 10
20 Svedson et al. 2004 Synthetic (Dronabinol) 2.5 mg – 
10.0 mg
Capsule Multiple Sclerosis Numeric Rating Scale 0 – 10
2004 Synthetic (Dronabinol) 2.5 mg – 
10.0 mg
Capsule Multiple Sclerosis Numeric Rating Scale
21 Toth et al. 2012 Synthetic (Nabilone) 2.0 mg – 4.0 
mg
Capsule Diabetes Numeric Rating Scale 0 – 10
22 Wade et al. 2003 Extract 2.5 mg 
THC / 2.5 
mg CBD
Oromucosal Spray Various Visual Analog Scale 0 – 100
Extract 2.5 mg THC Oromucosal Spray Various Visual Analog Scale 0 – 100
Extract 2.5 mg CBD Oromucosal Spray Various Visual Analog Scale 0 – 100
23 Wallace et al. 2015 Whole Plant 7% THC Humidified Diabetes Visual Analog Scale 0 – 10
Whole Plant 4% THC Humidified Diabetes Visual Analog Scale 0 – 10
Whole Plant 1 % THC Humidified Diabetes Visual Analog Scale 0 – 10
24 Ware et al. 2010 Whole Plant 9.4 % THC Smoke Neuropathic Pain Numeric Rating Scale 0 – 10
Whole Plant 6.0 % THC Smoke Neuropathic Pain Numeric Rating Scale 0 – 10
Whole Plant 2.5 % THC Smoke Neuropathic Pain Numeric Rating Scale 0 – 10
25 Wisley et al. 2008 Whole Plant 7.0 % THC Smoke Neuropathic Pain Visual Analog Scale 0 – 100
Whole Plant 3.5 % THC Smoke Neuropathic Pain Visual Analog Scale 0 – 100
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